American Century Companies’s Keros Therapeutics KROS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$906K Buy
84,680
+20,420
+32% +$227K ﹤0.01% 2425
2026
Q1
$709K Buy
64,260
+27,620
+75% +$427K ﹤0.01% 2429
2025
Q4
$746K Sell
36,640
-2,526
-6% -$44.3K ﹤0.01% 2404
2025
Q3
$620K Buy
+39,166
New +$579K ﹤0.01% 2451
2025
Q1
Sell
-328,920
Closed -$5.21M 2918
2024
Q4
$5.21M Buy
328,920
+31,251
+10% +$1.62M ﹤0.01% 1586
2024
Q3
$17.3M Sell
297,669
-501
-0.2% -$24.7K 0.01% 1087
2024
Q2
$13.6M Buy
298,170
+59,364
+25% +$3.19M 0.01% 1116
2024
Q1
$15.8M Buy
238,806
+24,209
+11% +$1.44M 0.01% 1019
2023
Q4
$8.53M Buy
214,597
+523
+0.2% +$16.4K 0.01% 1211
2023
Q3
$6.82M Buy
214,074
+71
+0% +$2.65K 0.01% 1218
2023
Q2
$8.6M Buy
214,003
+100,860
+89% +$4.42M 0.01% 1122
2023
Q1
$4.82M Buy
+113,143
New +$5.71M ﹤0.01% 1275

Other funds holding KROS

American Century Companies's KROS Position: Q2 2026 in Review

American Century Companies increased its Keros Therapeutics (KROS) stake by 32% in Q2 2026, buying an estimated $227K and bringing the position to 84,680 shares worth $906K. The position accounts for ﹤0.01% of the portfolio, ranked #2425.

American Century Companies first reported a position in KROS in Q1 2023 and has held it in 12 quarters since. The position peaked at $17.3M in Q3 2024. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • American Century Companies held 84,680 shares of Keros Therapeutics worth $906K as of Q2 2026.
  • American Century Companies bought 20,420 Keros Therapeutics shares in Q2 2026, an estimated $227K.
  • Keros Therapeutics made up ﹤0.01% of American Century Companies's portfolio in Q2 2026, its #2425 holding.
  • American Century Companies first reported a position in Keros Therapeutics in Q1 2023 and has held it in 12 quarters since.
  • American Century Companies's Keros Therapeutics position peaked at $17.3M in Q3 2024.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.